Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

JAMA : the Journal of the American Medical Association
Salim YusufOASIS-6 Trial Group

Abstract

Despite many therapeutic advances, mortality in patients with acute ST-segment elevation myocardial infarction (STEMI) remains high. The role of additional antithrombotic agents is unclear, especially among patients not receiving reperfusion therapy. To evaluate the effect of fondaparinux, a factor Xa inhibitor, when initiated early and given for up to 8 days vs usual care (placebo in those in whom unfractionated heparin [UFH] is not indicated [stratum 1] or unfractionated heparin for up to 48 hours followed by placebo for up to 8 days [stratum 2]) in patients with STEMI. Randomized double-blind comparison of fondaparinux 2.5 mg once daily or control for up to 8 days in 12,092 patients with STEMI from 447 hospitals in 41 countries (September 2003-January 2006). From day 3 through day 9, all patients received either fondaparinux or placebo according to the original randomized assignment. Composite of death or reinfarction at 30 days (primary) with secondary assessments at 9 days and at final follow-up (3 or 6 months). Death or reinfarction at 30 days was significantly reduced from 677 (11.2%) of 6056 patients in the control group to 585 (9.7%) of 6036 patients in the fondaparinux group (hazard ratio [HR], 0.86; 95% confidence in...Continue Reading

Citations

Mar 22, 2014·Drug Discoveries & Therapeutics·Zhang LiuFengshan Wang
May 15, 2013·Future Cardiology·Matthew Lumley, Divaka Perera
Dec 5, 2013·European Heart Journal·Martin MoserChristoph Bode
Mar 8, 2013·Future Cardiology·Thomas O BergmeijerJurriën M Ten Berg
Jul 1, 2007·Future Cardiology·Eugenia Nikolsky, Gregg W Stone
May 1, 2007·Future Cardiology·Eric R Bates
Mar 29, 2014·Current Treatment Options in Cardiovascular Medicine·Vikas Singh, Mauricio G Cohen
Feb 24, 2010·Journal des maladies vasculaires·A Godier, C-M Samama
Jul 27, 2010·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·W J KikkertJ P S Henriques
Aug 15, 2012·Canadian Journal of Physiology and Pharmacology·Petr Ostadal, Bohuslav Ostadal
Feb 28, 2007·Vascular Health and Risk Management·Alexander G G Turpie
Apr 1, 2008·Clinical Trials : Journal of the Society for Clinical Trials·Heather G Allore, Terrence E Murphy
Oct 30, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Abhinav GoyalPeter W F Wilson
Jun 25, 2009·Journal of Orthopaedic Trauma·Mohit BhandariUNKNOWN International Hip Fracture Research Collaborative
Apr 22, 2010·Vascular Health and Risk Management·François Schiele
Sep 22, 2010·Drug Design, Development and Therapy·Son V PhamPhuong-Anh T Pham
Sep 15, 2011·Vascular Health and Risk Management·Phuong-Anh PhamSon V Pham
Sep 16, 2010·Current Treatment Options in Cardiovascular Medicine·Marc Bonaca, Robert P Giugliano
Oct 23, 2012·Current Treatment Options in Cardiovascular Medicine·Charles V Pollack
Apr 25, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Dominick J Angiolillo, José Luis Ferreiro
Jun 12, 2013·Neurosciences : the Official Journal of the Pan Arab Union of Neurological Sciences·Adel Alhazzani
Nov 1, 2011·Clinical Medicine : Journal of the Royal College of Physicians of London·K A Breen, B J Hunt
Oct 15, 2009·European Heart Journal·Jean-Pierre BassandUNKNOWN OASIS 5 and OASIS 6 Investigators
Aug 31, 2010·European Heart Journal·UNKNOWN Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for CardDavid Taggart
Mar 23, 2011·European Heart Journal·Jan Steffel, Eugene Braunwald
Aug 28, 2012·European Heart Journal·UNKNOWN Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Doron Zahger
Aug 26, 2006·Nature Clinical Practice. Cardiovascular Medicine·Lori-Ann Linkins, Jeffrey I Weitz
Aug 26, 2006·Nature Clinical Practice. Cardiovascular Medicine·James J Ferguson, Gary M Idelchik
Feb 15, 2011·American Journal of Therapeutics·Suraj ChandrasekarRohit Arora
Nov 3, 2009·Journal of Thrombosis and Thrombolysis·Daniel S Weitz, Jeffrey I Weitz
Jan 22, 2010·Journal of Thrombosis and Thrombolysis·S Michael GharacholouJohn H Alexander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

Related Papers

The New England Journal of Medicine
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes InvestigatorsKeith A A Fox
The New England Journal of Medicine
Elliott M AntmanExTRACT-TIMI 25 Investigators
The New England Journal of Medicine
Gregg W StoneACUITY Investigators
The New England Journal of Medicine
Gregg W StoneHORIZONS-AMI Trial Investigators
Lancet
Z M ChenCOMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
© 2021 Meta ULC. All rights reserved